Castle BiosciencesCSTL +1.13%72 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates CSTL with a GF Score™ of 72/100 and a GF Value™ of $29.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 65 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 1538460% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Castle Biosciences is 0.00%.
The historical rank and industry rank for Castle Biosciences's Dividend Yield % or its related term are showing as below:
CSTL's Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.02 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Castle Biosciences Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs FLGT, MYGN, PRE: Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Dividend Yield % falls into.
Castle Biosciences (CSTL) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #999999 out of 65 companies in the Medical Diagnostics & Research industry.
Is Castle Biosciences' Dividend Yield % too high?
Castle Biosciences' current Dividend Yield % is 0.00%. Based on the distribution chart, Castle Biosciences ranks #999999 out of 65 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Castle Biosciences has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Dividend Yield % compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #999999 out of 65 companies for Dividend Yield %. This places Castle Biosciences in the lower half of its industry. The industry median Dividend Yield % is 2.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Diagnostics & Research company?
The median Dividend Yield % among Medical Diagnostics & Research companies is 2.02, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Yield % is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.15, compared to a current price of $22.37 — trading 23.3% below its estimated fair value. The current Dividend Yield % is 0.00%. Castle Biosciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $22.37 is trading 23.3% below its estimated GF Value™ of $29.15.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Dividend Yield %: 0.00%
GF Value™: $29.15 vs. price of $22.37 (23.3% below fair value)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
72GF Score
Get the complete analysis for CSTL
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
